A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma

Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of response and prevalent toxicities remain problematic. Identifying patients who are at high risk of disease progression, tox...

Descripción completa

Detalles Bibliográficos
Autores principales: Shouse, Geoffrey, Kaempf, Andy, Gordon, Max J., Artz, Andy, Yashar, David, Sigmund, Audrey M., Smilnak, Gordon, Bair, Steven M., Mian, Agrima, Fitzgerald, Lindsey A., Bajwa, Amneet, Jaglowski, Samantha, Bailey, Neil, Shadman, Mazyar, Patel, Krish, Stephens, Deborah M., Kamdar, Manali, Hill, Brian T., Gauthier, Jordan, Karmali, Reem, Nastoupil, Loretta J., Kittai, Adam S., Danilov, Alexey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362276/
https://www.ncbi.nlm.nih.gov/pubmed/36735393
http://dx.doi.org/10.1182/bloodadvances.2022009309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362276/
https://www.ncbi.nlm.nih.gov/pubmed/36735393
http://dx.doi.org/10.1182/bloodadvances.2022009309

Ejemplares similares